| Project/Area Number |
21791704
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Ophthalmology
|
|---|
| Research Institution | Wakayama Medical University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2009 – 2011
|
| Project Status |
Completed (Fiscal Year 2011)
|
| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2011: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2010: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2009: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Keywords | 眼病理学 / ソニックヘッジホッグ / 血管新生 / アンギオポイエチン / TIE2 / マクロファージ / VEGF / NF kappa B / PGE2 |
|---|
| Research Abstract |
Ocular neovascularization occurs in various diseases like wound healing, ischemic, age related macular degeneration, etc. Sever ocular neovascularization cases visual loss. Anti VEGF drugs are sometimes used for AMD. But in the other desease, we have no effective method to treat the ocular neovasclarizaiton. Angiopoietin is one of the angiogenic factors that are induced by Shh signals. In the laser induced choriodal neovasucularizaiton model in rat, Shh and Gli3, the Shh related signal trunsducion molecule, were immunohistochemically positive in the retinal pigment epithelium and retina around the laser spot. Shh may have an important role in the choroidal neovascularization via Ang expression. And conjunctibal injection of cyclopamin, Shh inhibitor, suppressed the choroidal neovasucularization. Shh may be aneffective target to treat the ocular neovascularization.
|
